AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06510335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender essential oil-based product system
Description: Participants used the study products in a sequential, additive manner approximately 30-60 minutes before bedtime each night for 6 weeks. Usage consists of the following:~* 20 drops of essential oil blend in approximately 250 mL of water in a diffuser, which operated for 8 hours at nighttime.~* 3 x 6 swipes of the topical stick on the upper chest area, and 2 x 3 swipes on the inside of each wrist for topical application.~* 2 capsules of the dietary supplement.~Participants used the essential oil blend alone for 1 week, then added the topical stick for another 1 week. Finally, participants used the essential oil blend, the topical stick, and the dietary supplement for four weeks.
Study NCT05027269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1001
Description: AOC 1001 will be administered by intravenous (IV) infusion.
Study NCT05027269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by intravenous (IV) infusion.
Study NCT06737471 — intervention group
Intervention type: OTHER
Intervention: Extensive rehabilitation treatment
Description: A 3-hour weekly rehabilitation treatment will be delivered to each patient for 15 weeks (45 hours) in an outpatient setting.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive.
Study NCT06498908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
Study NCT06498908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
Study NCT05477771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Description: The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
Study NCT06102161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wedge resection
Description: Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
Study NCT05839132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
Study NCT05839132 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: 20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
Study NCT05881850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.
Description: The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
Study NCT05293938 — intervention group
Intervention type: DRUG
Intervention: Obeticholic Acid 5 MG
Description: once daily, oral administration
Study NCT05293938 — intervention group
Intervention type: DRUG
Intervention: Obeticholic Acid 10 MG
Description: once daily, oral administration
Study NCT05293938 — intervention group
Intervention type: DRUG
Intervention: Standard of Care: UDCA
Description: No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
Study NCT05712382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent handbook
Description: Handbook motivating parents to discuss alcohol use with their college student.
Study NCT05076708 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IQOS
Description: All participants switch from cigarette smoking to IQOS use for a 14-day phase.
Study NCT03606746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDR-103
Description: MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
Study NCT06346275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
Study NCT06346275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
Study NCT06104683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06104683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study NCT05568745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)
Description: Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
Study NCT05568745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
Study NCT05568745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
Study NCT05712382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
Study NCT05162105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short rest (8 hour) between two consecutive shifts.
Description: Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
Study NCT05162105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 16 hour rest opportunity between to consecutive shifts.
Description: Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
Study NCT05336422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training on the risks associated with sun exposure
Description: 15-minute power point and presentation on the risks of sun exposure
Study NCT05184894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AKI in Care Transitions (ACT) program
Description: Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
Study NCT05958537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: Use of High-flow nasal oxygen at 60% 50 L/min.
Study NCT04822259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOURNEY II BCS Total Knee System
Description: Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
Study NCT04822259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOURNEY II CR Total Knee System
Description: Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
Study NCT05035394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract Surgery in a standardized fashion
Study NCT05035394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KDB
Description: Goniotomy with KDB glide will be performed at the end of Cataract Surgery
Study NCT05035394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Istent
Description: Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
Study NCT05747469 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: local anaesthetic injection
Description: Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
Study NCT05747469 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Human Adipose Allograft
Description: Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
Study NCT05712382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem-solving risky situations
Description: Identifying and planning for barriers to change are encouraged.
Study NCT05712382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recovering from slips
Description: Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
Study NCT06348212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei PS23
Description: 2 caps daily use
Study NCT06348212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: 2 caps daily use
Study NCT04715100 — intervention group
Intervention type: OTHER
Intervention: Observational group
Description: The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
Study NCT04234542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
Study NCT04234542 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Low Level Laser Therapy
Description: Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
Study NCT06304571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC006
Description: Specified dose on specified days
Study NCT04784975 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06354088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg
Description: All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.
Study NCT06354088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
Study NCT06354088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [1-13C] sodium acetate
Description: All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
Study NCT06354088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
Study NCT06354088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé BOOST Plus
Description: All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)
Study NCT05649774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Only Myofascial Release will be provided
Study NCT05649774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taping technique
Description: Only Kinesiotaping will be provided
Study NCT05649774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapy with taping
Description: Myofascial release will be provided followed by Kinesiotaping
Study NCT05649774 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Placebo Treatment will be given
Study NCT04630262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE Cementless CR Fixed Bearing
Description: Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
Study NCT04630262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE Cementless PS Fixed Bearing
Description: Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
Study NCT05509374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib 56 MG [Kyprolis]
Description: Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
Study NCT05509374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg per os (Day1-21)
Study NCT05509374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
Study NCT04678310 — intervention group
Intervention type: OTHER
Intervention: Support from the hospital palliative and end of life care volunteer service (developed for this study).
Description: Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
Study NCT05345587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THESS monitoring
Description: Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
Study NCT05673655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraoral trigger point injection by botox
Description: intraoral injection of trigger point of masseter muscle by botulinum toxin
Study NCT05673655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous trigger point injection by botox
Description: transcutaneous injection of masseter muscle by botulinum toxin
Study NCT06736717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: 20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle.
Study NCT06736717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALIRIFOX
Description: Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle.
Study NCT04783727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Individualised treatment duration based on RNA transcriptomic model
Description: Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
Study NCT06432426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality training group
Description: Participants will be given virtual reality games on Nintendo Wii Fit® and its peripheral Balance Board system. This equipment offers safe and engaging training protocols. Additionally, it ensures physical exercise in the three planes of movement (sagittal, frontal, and transverse) and with three difficulty levels, thus providing a linear progressive demand.
Study NCT06432426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical exercise group
Description: Participants will be submitted to a standard physical exercise program based on the ACSM guidelines. Resistance training will involve exercises for arms and legs, using bodyweight self-loading and external weights. Balance exercises will include the three planes of movement.
Study NCT04856618 — intervention group
Intervention type: BIOLOGICAL
Intervention: Massive Transfusion of Allogeneic Blood
Description: Massive Transfusion of Allogeneic Blood, > pRBCs
Study NCT04791826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-screen electronic alert
Description: On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
Study NCT06413394 — intervention group
Intervention type: OTHER
Intervention: environmental education
Description: environmental education
Study NCT05544955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isolate whey protein prior to and immediately after resistance training
Description: This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
Study NCT05544955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isolate whey protein 3 hours prior to and 3 hours after resistance training
Description: This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
Study NCT06737042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: GLP-1
Study NCT05551988 — intervention group
Intervention type: OTHER
Intervention: Retrospective observational study of diabetic foot ulcer
Description: This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
Study NCT06444100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impact of structural training on child abuse
Description: A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training.
Study NCT05371197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with PD-L1 inhibitor
Description: Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles